Kelly Aubertin

Kelly Aubertin

Auto-generated profile, based on publicly available information

Kelly Aubertin

Laboratoire Matière et Systèmes Complexes (MSC) Université Paris Cité, CNRS UMR 7057 45 rue des Saints‐Pères 75006 Paris France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
ASAmanda K.A. Silva
Amanda K.A. Silva
NLNathalie Luciani
Nathalie Luciani
FGFlorence Gazeau
Florence Gazeau
KAKelly Aubertin
Kelly Aubertin
SBStéphanie Bonneau
Stéphanie Bonneau
Claire WilhelmClaire Wilhelm
Claire Wilhelm

18 October 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KAKelly Aubertin
Kelly Aubertin
ASAmanda K. A. Silva
Amanda K. A. Silva
NLNathalie Luciani
Nathalie Luciani
AEAna Espinosa
Ana Espinosa
ADAurélie Djemat
Aurélie Djemat
Claire WilhelmClaire Wilhelm
Claire Wilhelm
Photodynamic therapy is an emerging cancer treatment that is particularly adapted for localized malignant tumor. The phototherapeutic agent is generally injected in the bloodstream and circulates in the whole organism as a chemotherapeutic agent, but needs light triggering to induce localized therapeutic effects. We found that one of the responses of in vitro and in vivo cancer cells to photodynamic therapy was a massive production and emission of extracellular vesicles (EVs): only 1 hour after the photo-activation, thousands of vesicles per cell were emitted in the extracellular medium. A similar effect has been found after treatment with Doxorubicin (chemotherapy), but far less EVs were produced, even 24 hours after the treatment. Furthermore, we found that the released EVs could transfer extracellular membrane components, drugs and even large intracellular objects to naive target cells. In vivo, photodynamic treatment and chemotherapy increased the levels of circulating EVs several fold, confirming the vast induction of cancer cell vesiculation triggered by anti-cancer therapies.

2 November 2016 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
MJMichael Jermyn
Michael Jermyn
JDJoannie Desroches
Joannie Desroches
KAKelly Aubertin
Kelly Aubertin
KSKarl St-Arnaud
Karl St-Arnaud
WMWendy-Julie Madore
Wendy-Julie Madore
FLFrédéric Leblond
Frédéric Leblond
There is an urgent need for improved techniques for disease detection. Optical spectroscopy and imaging technologies have potential for non- or minimally-invasive use in a wide range of clinical applications. The focus here, in vivo Raman spectroscopy (RS), measures inelastic light scattering based on interaction with the vibrational and rotational modes of common molecular bonds in cells and tissue. The Raman ‘signature’ can be used to assess physiological status and can also be altered by disease. This information can supplement existing diagnostic (e.g. radiological imaging) techniques for disease screening and diagnosis, in interventional guidance for identifying disease margins, and in monitoring treatment responses. Using fiberoptic-based light delivery and collection, RS is most easily performed on accessible tissue surfaces, either on the skin, in hollow organs or intra-operatively. The strength of RS lies in the high biochemical information content of the spectra, that characteristically show an array of very narrow peaks associated with specific chemical bonds. This results in high sensitivity and specificity, for example to distinguish malignant or premalignant from normal tissues. A critical issue is that the Raman signal is often very weak, limiting clinical use to point-by-point measurements. However, non-linear techniques using pulsed-laser sources have been developed to enable in vivo Raman imaging. Changes in Raman spectra with disease are often subtle and spectrally distributed, requiring full spectral scanning, together with the use of tissue classification algorithms that must be trained on large numbers of independent measurements. Recent advances in instrumentation and spectral analysis have substantially improved the clinical feasibility of RS, so that it is now being investigated with increased success in a wide range of cancer types and locations, as well as for non-oncological conditions. This review covers recent advances and continuing challenges, with emphasis on clinical translation.

5 May 2013 in ACS Nano
Verified
Journal Article
Closed access
ASAmanda K. A. Silva
Amanda K. A. Silva
JKJelena Kolosnjaj-Tabi
Jelena Kolosnjaj-Tabi
SBStephanie Bonneau
Stephanie Bonneau
IMIris Marangon
Iris Marangon
NBNicole Boggetto
Nicole Boggetto
Claire WilhelmClaire Wilhelm
Claire Wilhelm

24 October 2014 in ACS Nano
Verified
Journal Article
Closed access
XLXiaojie Liu
Xiaojie Liu
IMIris Marangon
Iris Marangon
GMGeorgian Melinte
Georgian Melinte
Claire WilhelmClaire Wilhelm
Claire Wilhelm
CMCécilia Ménard-Moyon
Cécilia Ménard-Moyon
DBDominique Bégin
Dominique Bégin

1 November 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
MPMax Piffoux
Max Piffoux
JVJeanne Volatron
Jeanne Volatron
Kondareddy CherukulaKondareddy Cherukula
Kondareddy Cherukula
KAKelly Aubertin
Kelly Aubertin
CWClaire Wilhelm
Claire Wilhelm
FGFlorence Gazeau
Florence Gazeau